Pros and cons of vitamin k antagonists and non-vitamin k antagonist oral anticoagulants

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 2, 2015, Pages 178-187

  Riva, Nicoletta ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

direct factor Xa inhibitor; direct thrombin inhibitor; vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; VITAMIN K GROUP;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MONITORING; DYSPEPSIA; EMBOLISM; FOOD DRUG INTERACTION; FOOT DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; LABORATORY TEST; LUNG EMBOLISM; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PURPLE TOE SYNDROME; RISK BENEFIT ANALYSIS; SKIN NECROSIS; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; METABOLISM; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; EMBOLISM; HUMANS; STROKE; VITAMIN K;

EID: 84923924319     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1544231     Document Type: Article

References (94)

1. Husted S., de Caterina R., Andreotti F., et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost: 2014; 111 5 781 782
2. Whitlon D. S., Sadowski J. A., Suttie J. W. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry: 1978; 17 8 1371 1377
3. Ageno W., Gallus A. S., Wittkowsky A., Crowther M., Hylek E. M., Palareti G.; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e44S e88S
4. Harenberg J. New anticoagulants in atrial fibrillation. Semin Thromb Hemost: 2009; 35 6 574 585
5. Hankey G. J., Eikelboom J. W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation: 2011; 123 13 1436 1450
6. Wong P. C., Pinto D. J., Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis: 2011; 31 4 478 492
7. Furugohri T., Isobe K., Honda Y., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost: 2008; 6 9 1542 1549
8. Perzborn E., Roehrig S., Straub A., Kubitza D., Mueck W., Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol: 2010; 30 3 376 381
9. Hirsh J. Oral anticoagulant drugs. N Engl J Med: 1991; 324 26 1865 1875
10. Fung E., Patsopoulos N. A., Belknap S. M., et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost: 2012; 38 8 893 904 [Erratum in: Semin Thromb Hemost. 2013;39(1):112]
11. Godbillon J., Richard J., Gerardin A., Meinertz T., Kasper W., Jähnchen E. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol: 1981; 12 5 621 629
12. Kubitza D., Becka M., Wensing G., Voith B., Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol: 2005; 61 12 873 880
13. Bounameaux H., Camm A. J. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs: 2014; 74 11 1209 1231
14. Reilly P. A., Lehr T., Haertter S., et al. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol: 2014; 63 4 321 328
15. Kubitza D., Roth A., Becka M., et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol: 2013; 76 1 89 98
16. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace: 2013; 15 5 625 651
17. Neumann I., Rada G., Claro J. C., et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med: 2012; 156 10 710 719
18. Salazar C. A., Malaga G., Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database Syst Rev: 2010; 4 CD005981
19. Albertsen I. E., Larsen T. B., Rasmussen L. H., Overvad T. F., Lip G. Y. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis. Drugs: 2012; 72 13 1755 1764
20. van der Hulle T., Kooiman J., den Exter P. L., Dekkers O. M., Klok F. A., Huisman M. V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost: 2014; 12 3 320 328
21. Konstantinides S. V., Torbicki A., Agnelli G., et al. Authors/Task Force Members; Authors/Task Force Members. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Endorsed by the European Respiratory Society (ERS). Eur Heart J: 2014; 35 43 3033 3073
22. Schulman S., Kearon C., Kakkar A. K., et al. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med: 2013; 368 8 709 718
23. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
24. Agnelli G., Buller H. R., Cohen A., et al. PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med: 2013; 368 8 699 708
25. Ruff C. T., Giugliano R. P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet: 2014; 383 9921 955 962
26. Camm A. J., Lip G. Y., De Caterina R., et al. ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J: 2012; 33 21 2719 2747
27. Cappato R., Ezekowitz M. D., Klein A. L., et al. on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J: 2014; 35 47 3346 3355
28. Providência R., Marijon E., Albenque J. P., et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace: 2014; 16 8 1137 1144
29. Eikelboom J. W., Connolly S. J., Brueckmann M., et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med: 2013; 369 13 1206 1214
30. Oldgren J., Wallentin L., Alexander J. H., et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J: 2013; 34 22 1670 1680
31. Wiedermann C. J., Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res: 2008; 122 02 S13 S18
32. Linkins L. A., Choi P. T., Douketis J. D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med: 2003; 139 11 893 900
33. Sallah S., Thomas D. P., Roberts H. R. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost: 1997; 78 2 785 790
34. Giugliano R. P., Ruff C. T., Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
35. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
36. Dentali F., Riva N., Crowther M., Turpie A. G., Lip G. Y., Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation: 2012; 126 20 2381 2391
37. Chatterjee S., Sardar P., Biondi-Zoccai G., Kumbhani D. J. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol: 2013; 70 12 1486 1490
38. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
39. Agnelli G., Buller H. R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 9 799 808
40. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151 [Erratum in: N Engl J Med 2010; 363(19): 1877]
41. Schulman S., Kearon C., Kakkar A. K., et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
42. Uchino K., Hernandez A. V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med: 2012; 172 5 397 402
43. Douxfils J., Buckinx F., Mullier F., et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc: 2014; 3 3 e000515
44. Lip G. Y., Lane D. A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med: 2010; 123 9 785 789
45. Artang R., Rome E., Nielsen J. D., Vidaillet H. J. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol: 2013; 112 12 1973 1979
46. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem: 2013; 59 2 353 362
47. Mearns E. S., White C. M., Kohn C. G., et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J: 2014; 12 14
48. Mearns E. S., Kohn C. G., Song J. S., et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res: 2014; 134 2 310 319
49. Wan Y., Heneghan C., Perera R., et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes: 2008; 1 2 84 91
50. Veeger N. J., Piersma-Wichers M., Tijssen J. G., Hillege H. L., van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol: 2005; 128 4 513 519
51. Baker W. L., Cios D. A., Sander S. D., Coleman C. I. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm: 2009; 15 3 244 252
52. Garcia D., Barrett Y. C., Ramacciotti E., Weitz J. I. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost: 2013; 11 2 245 252
53. Lippi G., Favaloro E. J., Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost: 2014; 40 7 756 765
54. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost: 2010; 103 6 1116 1127
55. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost: 2013; 11 756 760
56. Di Minno A., Spadarella G., Prisco D., Franchini M., Lupoli R., Di Minno M. N. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost: 2013; 39 7 840 846
57. Harenberg J., Du S., Weiss C., Krämer R., Hoppensteadt D., Walenga J.; working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost: 2014; 12 5 801 804
58. Harenberg J., Du S., Krämer S., et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost: 2013; 39 1 66 71
59. Makris M., van Veen J. J., Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis: 2010; 29 2 171 181
60. Franchini M., Lippi G. Prothrombin complex concentrates: an update. Blood Transfus: 2010; 8 3 149 154
61. Dentali F., Marchesi C., Pierfranceschi M. G., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost: 2011; 106 3 429 438
62. Hickey M., Gatien M., Taljaard M., Aujnarain A., Giulivi A., Perry J. J. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation: 2013; 128 4 360 364
63. Hanger H. C., Geddes J. A., Wilkinson T. J., Lee M., Baker A. E. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J: 2013; 43 3 308 316
64. Woo C. H., Patel N., Conell C., et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg: 2014; 81 1 110 115
65. Majeed A., Meijer K., Larrazabal R., et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost: 2014; 111 2 233 239
66. Sarode R., Milling T. J. Jr, Refaai M. A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation: 2013; 128 11 1234 1243
67. Holbrook A., Schulman S., Witt D. M., et al. American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e152S e184S
68. Voils S. A., Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res: 2012; 130 6 833 840
69. Rosovsky R. P., Crowther M. A. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology (Am Soc Hematol Educ Program): 2008; 36 38
70. Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., Meijers J. C., Buller H. R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
71. Levi M., Moore K. T., Castillejos C. F., et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost: 2014; 12 9 1428 1436
72. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J. L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost: 2012; 108 2 217 224 [Erratum in: Thromb Haemost. 2013;109(1):169]
73. Siegal D. M., Garcia D. A., Crowther M. A. How I treat target-specific oral anticoagulant-associated bleeding. Blood: 2014; 123 8 1152 1158
74. Schiele F., van Ryn J., Canada K., et al. A specific antidote for dabigatran: functional and structural characterization. Blood: 2013; 121 18 3554 3562
75. Crowther M., Kitt M., Lorenz T., et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. [abstract] J Thromb Haemost: 2013; 11 02 30
76. Crowther M., Mathur V., Kitt M., et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood: 2013; 122 3636 (abstract)
77. Kaatz S., Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis: 2013; 36 2 195 202
78. Khadzhynov D., Wagner F., Formella S., et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost: 2013; 109 4 596 605
79. thed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e326S e350S
80. Spyropoulos A. C., Douketis J. D. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood: 2012; 120 15 2954 2962
81. Schulman S., Healey J. S., Douketis J. D., Delaney J., Morillo C. A. Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial. Thromb Res: 2014; 134 4 814 818
82. Birnie D. H., Healey J. S., Wells G. A., et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med: 2013; 368 22 2084 2093
83. Horne R., Weinman J., Barber N., Elliot R., Morgan M. Concordance, adherence and compliance in medicine taking. Report for the National Coordinating Centre for NHS Service Delivery and Organization R & D (NCCSDO). Available at: http://www.nets.nihr.ac.uk/-data/assets/pdf-file/0009/64494/FR-08-1412-076.pdf. Accessed October 28, 2014
84. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med: 2005; 353 5 487 497
85. Di Minno A., Spadarella G., Tufano A., Prisco D., Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res: 2014; 133 5 699 704
86. Suryanarayan D., Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin k antagonist oral anticoagulants and old oral anticoagulants in the real world-a problem or a myth? Semin Thromb Hemost: 2014; 40 8 852 859
87. Platt A. B., Localio A. R., Brensinger C. M., et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf: 2008; 17 9 853 860
88. Borg Xuereb C., Shaw R. L., Lane D. A. Patients' and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns: 2012; 88 2 330 337
89. Tang E. O., Lai C. S., Lee K. K., Wong R. S., Cheng G., Chan T. Y. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother: 2003; 37 1 34 39
90. Clarkesmith D. E., Pattison H. M., Lip G. Y., Lane D. A. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE: 2013; 8 9 e74037
91. Ageno W., Crowther M., Baglin T., Falanga A., Buller H., Palareti G.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost: 2013; 11 1 177 179
92. Laufs U., Rettig-Ewen V., Böhm M. Strategies to improve drug adherence. Eur Heart J: 2011; 32 3 264 268
93. Schulman S., Shortt B., Robinson M., Eikelboom J. W. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost: 2013; 11 7 1295 1299
94. Shore S., Carey E. P., Turakhia M. P., et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans health administration. Am Heart J: 2014; 167 6 810 817